Approval · Notice of Compliance 29335 · 2022
SUMATRIPTAN INJECTION, USP: Notice of Compliance 29335
Issued October 28, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29335
- Date
- October 28, 2022
- Company
- Dr Reddys Laboratories Ltd
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN INJECTION, USP | 02532387 | Marketed |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML